

PRESS RELEASE

APPROVAL OF THE CORPORATE EVENTS CALENDAR FOR 2017

Capua, 26 January 2017 – The Board of Directors of Pierrel S.p.A., meeting today, has approved pursuant to Article 2.6.2 (*Information requirements*) of the Regulations of the Market that is organised and managed by Borsa Italiana S.p.A. – decided on 10 September 2009 and approved by the CONSOB with its decision no. 17026 of 7 October 2009, as subsequently revised and updated – the calendar of corporate events of Pierrel S.p.A. for 2017, as summarised in the following table.

Date	Event
Week of 3 – 7 April 2017	Board of Directors meeting to approve the draft financial statements for the year ended 31 December 2016
Week of 9 – 15 May 2017	Board of Directors meeting to approve on a voluntary basis the interim management report for the period ended 31 March 2017
Week of 22 – 26 May 2017	General Meeting of shareholders to approve the financial statements for the year ended December 2016
Week of 2 – 8 August 2017	Board of Directors meeting to approve the abbreviated half-yearly consolidated financial statements at 30 June 2017
Week of 8 – 15 November 2017	Board of Directors meeting to approve on a voluntary basis the interim management report for the period ended 30 September 2017

The precise date of Directors and shareholders meetings, as well as possible changes to the above, will be communicated to the regulatory authorities and the public in the timeframe and in the manner required by law and applicable regulations.

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical industry, specialising in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics.

Pierrel has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A. *Investor Relations* Raffaele Petrone E-mail: <u>investor.relations@pierrelgroup.com</u> tel. +39 0823 626 111 fax +39 0823 626 228 Global Consult s.r.l. Media Relations Rossana Del Forno E-mail: <u>areacomunicazione@globalconsultsrl.com</u> tel. +39 333 6178665